Pancragen vs Cagrilintide
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
PancragenGLP-1 / Weight Loss Agonists
Cagrilintide- Summary
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- ~7–10 days
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
- Frequency
- Daily for 10–30 days
- Once weekly
- Key Benefits
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
- Synergistic appetite suppression complementing GLP-1 receptor agonists
- Reduces post-meal glucagon excursions improving glycemic control
- Slows gastric emptying contributing to prolonged satiety
- Once-weekly dosing via subcutaneous injection
- Potential for greater weight loss than semaglutide monotherapy
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Nausea (most common, especially during titration)
- Vomiting
- Decreased appetite
- Diarrhea
- +2 more
- Stacks With
- —
- —